The study was published in the journal Scientific Reports and conducted by researchers from IBM’s T.J. Watson Research Center in Yorktown Heights, N.Y., and the CHDI Foundation. They used MRI data to train an algorithm to recognize differences in the neural activity of Huntington’s patients based on how far the disease had progressed, and how rapidly.
According to an IBM blog post by two of the study’s authors, “The results demonstrate that measuring the potential progression of [Huntington’s disease] could eventually be done from a single brain scan, acquired in one visit.”
This ability would not only speed and improve disease diagnosis and treatment, but could also improve clinical trial design by identifying only those patients most likely to respond to experimental treatments, they wrote, adding, “These are only the first of a series of results from combined IBM and CHDI research efforts driven by a goal of hoping to use personalized medicine to further advance drug development for this disease.”
More articles on AI:
An AI algorithm detected the coronavirus outbreak a week before the CDC
Huntington Hospital implements AI-powered stroke detection platform
Health Catalyst becomes 1st healthcare member of Partnership on AI
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
